<p>在今天发布的一份报告中，美国银行证券的杰森·杰伯里维持了对 Royalty Pharma 的买入评级，目标价为 62.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks 的数据，杰伯里是一位五星级分析师，平均回报率为 18.9%，成功率为 61.32%。杰伯里覆盖医疗保健行业，专注于 BioMarin Pharmaceutical、Ionis Pharmaceuticals 和 Alkermes 等股票。</p>
<p>Royalty Pharma 的分析师共识为强烈买入，目标价共识为 59.43 美元。</p>

RPRX

医疗业 ETF - Vanguard

美国制药 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

<p>美国银行证券对 Royalty Pharma (RPRX) 维持买入评级，目标价为 62.00 美元。分析师 Jason Gerberry 是一位五星级分析师，平均回报率为 18.9%，他强调了 Royalty Pharma 的强烈买入共识和目标价共识为 59.43 美元。Gerberry 还覆盖了其他医疗保健股票，如 BioMarin Pharmaceutical 和 Ionis Pharmaceuticals</p>

<p>In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma, with a price target of $62.00.</p>
<div class="lb-trans"><p>在今天发布的一份报告中，美国银行证券的杰森·杰伯里维持了对 Royalty Pharma 的买入评级，目标价为 62.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.9% and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Alkermes.</p>
<div class="lb-trans"><p>根据 TipRanks 的数据，杰伯里是一位五星级分析师，平均回报率为 18.9%，成功率为 61.32%。杰伯里覆盖医疗保健行业，专注于 BioMarin Pharmaceutical、Ionis Pharmaceuticals 和 Alkermes 等股票。</p>
</div><p>Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $59.43.</p>
<div class="lb-trans"><p>Royalty Pharma 的分析师共识为强烈买入，目标价共识为 59.43 美元。</p>
</div>

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

Tip Ranks

Royalty Pharma PLC - CL

美国银行

拜玛林制药

Ionis制药

阿尔凯默斯

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美国银行证券维持对 Royalty Pharma（RPRX）的买入评级